Global
EN CN
News
Strive forward with partners and pursue dreams
Big congratulations to Dr. Yan Feng of Leaddingtac was awarded with one of the first few of "Pearl Leading Talent" in Pudong New Area
2023-12-12

1.jpg

On December 6, 2023 Pudong International Talent Port Forum, with the theme of "Leadership, Gathering Momentum and Leap", was held at the Zhangjiang Science Hall. The first batch of "Pearl Program" talents of Pudong New Area was announced in the main forum, and honorary certificates and trophies were awarded.

冯总领军人才奖杯.jpg

Leadingtac's targeted protein degradation programmed, under the leadership of Dr. Yan Feng, and the generous support from other member staffs, has successfully passed the rigorous evaluation of the talent expert group of the Pudong New Area Committee.  Dr. Yan Feng, as the founder and general manager of the company, won the title of "Pearl Leading Talent" of the Pudong New Area for the year of 2023.


About "Pearl Talent Plan":

The "Pearl Plan" is a special policy to support the development of four types of strategic scientific and technological talents by focusing on the major tasks of building a leading area for the construction of socialist modernization and a high-level talent highland, relying on national laboratories, high-level research universities, national scientific research institutes, and scientific and technological leading enterprises, introducing globally a group of high-level overseas talents, who already stood at the international scientific and technological frontiers and led the independent innovation of science and technology, discovering and cultivating a group of innovative and entrepreneurial talents with leading roles or high growth potentials, focusing on the three major pioneering industries and other key industries, and keeping in view the cultivation of new racetracks.


About Leadingtac:

Founded in 2019, Leadingtac is a clinical-stage biopharmaceutical company dediated to the discovery and development of First-in-class/Best-in-class small molecule innovative therapies using Protein Degradation (TPD) drug development platform with a focus on autoimmune and oncology, two therapeutic areas with great clinical unmet needs: autoimmune disease and oncology, providing breakthrough therapeutic solutions for patients. Located in Zhangjiang Science City, Shanghai, China, Leadingtac has nearly 1000 square meters of laboratory and office space, 20 employees, and has raised nearly CNY¥100 million in funding since its inception 4 years ago.



Company Mailbox
Incoming Email
Official Account